Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials

INTRODUCTION: Temporary dose modifications, such as reductions or interruptions, may allow patients to better manage adverse events (AEs) associated with pirfenidone use and continue treatment for idiopathic pulmonary fibrosis (IPF). However, the impact of such dosing adjustments on efficacy and saf...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Open Respir Res
Hlavní autoři: Nathan, Steven D, Lancaster, Lisa H, Albera, Carlo, Glassberg, Marilyn K, Swigris, Jeffrey J, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Limb, Susan L, Petzinger, Ute, Noble, Paul W
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2018
Témata:
Interstitial Lung Disease
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089326/
https://ncbi.nlm.nih.gov/pubmed/30116539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2018-000323
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky